ClinicalTrials.gg
Sign In
Not yet recruitingNCT06907992SCATUpdated Apr 4, 2025

A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia

An observational study in Candidemia, sponsored by Augusta University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Augusta University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to assess whether a seven-day course of standard of care (echinocandin) antifungal therapy is non-inferior to a 14-day course of echinocandin antifungal therapy in patients with uncomplicated candidemia in terms of clinical, mycologic, adverse events and all cause mortality.

02

Conditions studied

  • Candidemia

Browse trials for

Keywords

  • candidemia
  • uncomplicated candidemia
  • antifungal therapy
  • echinocandin
  • caspofungin
  • micafungin
  • rezafungin
  • anidulafungin
03

In context

Candidemia

67 studies on the registry are indexed under Candidemia; 4 are open to participants now.

This study's planned enrollment of 150 is below the median of 250 across 25 observational studies indexed under Candidemia.

Browse Candidemia studies →

Lead sponsor

Augusta University is the lead sponsor of 179 studies on the registry; 25 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Browse Augusta University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants will be recruited from:

A. Inpatient settings based on positive blood cultures for candidemia. B. Daily review of microbiology labs C. Referrals from investigators, ICUs and hospital unit personnel

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥ 18 years of age
  2. Uncomplicated candidemia (positive blood culture only). No evidence of invasive candidiasis at day 1 or until day 7.
  3. Received \< 5 days of prior antifungal therapy
  4. Informed Consent for randomization
  5. Patients that did not consent to randomization have consented to be used as a natural history (controls) and will allow collection of available data from the medical record.

Exclusion criteria

Exclusion Criteria:

  1. Inadequate source control (e.g., unable to remove endovascular devices, urinary catheters).
  2. Invasive candidiasis of any type (e.g., deep seated candidiasis from sources other than blood)
  3. Abnormal LFTs > 10-fold
  4. Greater than 5 days of prior antifungal therapy
  5. Endovascular devices that cannot be removed.
  6. Immunocompromised patients (AIDS/HIV; solid organ transplant, bone marrow transplant patients, oncology patients receiving chemotherapy, neutropenic patients (ANC of \< 1,500 cells/L
  7. Neutropenic at time of consent (what does this mean)
  8. Break-through candidemia (people with prior candidemia who relapsed) after treatment with antifungal therapy)
  9. Unable to provide informed consent from either the patient or legally authorized authority (LAR)
  10. Expected mortality within 96 hours
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • 7 Days

    Study participants randomized to the 7 Day group will receive the short-course antifungal therapy for 7 days.

    Drug: Antifungal treatment

  • 14 Days

    Study participants randomized to the 14 Day group will receive the standard of care antifungal therapy for 14 days.

    Drug: Antifungal treatment

Interventions

  • DrugAntifungal treatment

    Short-course antifungal therapy (7 days) versus standard of care antifungal therapy (14 days)

06

What researchers measure

Primary outcomes

  1. Eradication of candida from the blood at day 7 or day 14

    Blood culture monitoring at day 7 and day 14

    Time frame: 14 Days

07

Study locations

1 site
  • Augusta University
    Augusta, Georgia 30912, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for May 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 3, 2025
StartEst.
May 1, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06907992
Lead sponsor
Augusta University
Responsible party
Jose Vazquez (Principal Investigator, Augusta University) — Principal investigator
First posted
Apr 3, 2025
Start date
May 1, 2025 (estimated)
Primary completion
May 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 4, 2025

Study contacts

Aprile Osborn, MSN
Contact
aosborn@augusta.edu
706-721-0309
Jose Vazquez, MD
principal investigator · Augusta University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Candidemia →

Other studies from this sponsor

Augusta University →

Start the discussion